Glycopyrrolate and formoterol fumarate

FDA Drug Profile — BEVESPI AEROSPHERE

Drug Details

Generic Name
Glycopyrrolate and formoterol fumarate
Brand Names
BEVESPI AEROSPHERE
Application Number
NDA208294
Sponsor
AstraZeneca Pharmaceuticals LP
NDC Codes
1
Dosage Forms
AEROSOL, METERED
Routes
RESPIRATORY (INHALATION)
Active Ingredients
FORMOTEROL FUMARATE, GLYCOPYRROLATE

Indications and Usage

1 INDICATIONS AND USAGE BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.2 )] . BEVESPI AEROSPHERE is a combination of glycopyrrolate, an anticholinergic, and formoterol fumarate, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm or for the treatment of asthma. ( 1 , 5.1 , 5.2 )